AAAAAA

   
Results: 1-25 |
Results: 25
Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patients
Authors: Fidouh-Houhou, N Duval, X Bissuel, F Bourbonneux, V Flandre, P Ecobichon, JL Jordn, MC Vilde, JL Brun-Vezinet, F Leport, C
Citation: N. Fidouh-houhou et al., Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patients, CLIN INF D, 33(8), 2001, pp. 1406-1411
HIV type 1 genetic diversity and genotypic drug susceptibility in the Republic of Moldova
Authors: Pandrea, I Descamps, D Collin, G Robertson, DL Damond, F Dimitrienco, V Gheorghita, S Pecec, M Simon, F Brun-Vezinet, F Apetrei, C
Citation: I. Pandrea et al., HIV type 1 genetic diversity and genotypic drug susceptibility in the Republic of Moldova, AIDS RES H, 17(13), 2001, pp. 1297-1304
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting
Authors: Miller, V Vandamme, AM Loveday, C Staszewski, S Lundgren, J Youle, M Ait-Khaled, M Boucher, C Brun-Vezinet, F Dedes, N Giaquinto, C Hertogs, K Houyez, F Perrin, L Pillay, D Schmit, JC Schuurman, R Lange, J Banhegyi, D Biondi, G Broekhuizen, A Bush-Donovan, C Camacho, R Carlier, H Clavel, F Clotet, B Clumeck, N Colebunders, R De Clerq, K De Jaegher, JJ De Schrijver, G De Smet, K Hall, W Harrigan, R Hatzakis, A Hellmann, N Hoetelmans, R Holtzer, C Katlama, C Larder, D Loriaux, E McCreedy, B Mulcahy, F Opravil, M Phillips, A Ruiz, N Shulse, E Sonnerborg, A Soriano, V Steel, H Vella, S Williams, A
Citation: V. Miller et al., Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting, AIDS, 15(3), 2001, pp. 309-320
Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study
Authors: Descamps, D Calvez, V Izopet, J Bluffet-Janvresse, C Schmuck, A Colson, P Ruffault, A Maillard, A Masquelier, B Cottalorda, J Harzic, M Brun-Vezinet, F Costagliola, D
Citation: D. Descamps et al., Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study, AIDS, 15(14), 2001, pp. 1777-1782
Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR
Authors: Damond, F Descamps, D Farfara, I Telles, JN Puyeo, S Campa, P Lepretre, A Matheron, S Brun-Vezinet, F Simon, F
Citation: F. Damond et al., Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR, J CLIN MICR, 39(12), 2001, pp. 4264-4268
V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant
Authors: Plantier, JC Damond, F Souquieres, S Brun-Vezinet, F Simon, F Barin, F
Citation: Jc. Plantier et al., V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant, J CLIN MICR, 39(10), 2001, pp. 3803-3807
Genotypic and penotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase(RT): Multicenter study of patients treated with RT inhibitors
Authors: Masquelier, B Race, E Tamalet, C Descamps, D Izopet, J Buffet-Janvresse, C Ruffault, A Mohammed, AS Cottalorda, J Schmuck, A Calvez, V Dam, E Fleury, H Brun-Vezinet, F
Citation: B. Masquelier et al., Genotypic and penotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase(RT): Multicenter study of patients treated with RT inhibitors, ANTIM AG CH, 45(6), 2001, pp. 1836-1842
Variability of human immunodeficiency virus type 2 (HIV-2) infecting patients living in France
Authors: Damond, F Apetrei, C Robertson, DL Souquiere, S Lepretre, A Matheron, S Plantier, JC Brun-Vezinet, F Simon, F
Citation: F. Damond et al., Variability of human immunodeficiency virus type 2 (HIV-2) infecting patients living in France, VIROLOGY, 280(1), 2001, pp. 19-30
Changes in human immunodeficiency virus type 1 populations after treatmentinterruption in patients failing antiretroviral therapy
Authors: Hance, AJ Lemiale, V Izopet, J Lecossier, D Joly, V Massip, P Mammano, F Descamps, D Brun-Vezinet, F Clavel, F
Citation: Aj. Hance et al., Changes in human immunodeficiency virus type 1 populations after treatmentinterruption in patients failing antiretroviral therapy, J VIROLOGY, 75(14), 2001, pp. 6410-6417
Long-term immunologic response in HIV-infected patients with CD4 cell counts <= 50/mm(3) when initiating protease inhibitor therapy.
Authors: Le Moing, V Eid, Z Ecobichon, JL Duval, X Longuet, P Elbim, C Brun-Vezinet, F Leport, C Vilde, JL
Citation: V. Le Moing et al., Long-term immunologic response in HIV-infected patients with CD4 cell counts <= 50/mm(3) when initiating protease inhibitor therapy., ANN MED IN, 152(1), 2001, pp. 11-14
Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy
Authors: Le Moing, V Chene, G Masquelier, B Sicard, D Brun-Vezinet, F Reynes, J Raffi, F
Citation: V. Le Moing et al., Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy, J ACQ IMM D, 24(1), 2000, pp. 82-83
Conditions of selection of 'thymidine analogue mutations' (TAMs) in naive patients receiving different antiretroviral combinations including d4T.
Authors: Mouroux, M Izopet, J Descamps, D Delaugerre, C Yvon-Groussin, A Angleraud, F Coutellier, A Bonmarchand, M Valantin, MA Matheron, S Agut, H Katlama, C Brun-Vezinet, F Calvez, V
Citation: M. Mouroux et al., Conditions of selection of 'thymidine analogue mutations' (TAMs) in naive patients receiving different antiretroviral combinations including d4T., PATH BIOL, 48(5), 2000, pp. 508-512
HIV-1 diversity in France, 1996-1998
Authors: Couturier, E Damond, F Roques, P Fleury, H Barin, F Brunet, JB Brun-Vezinet, F Simon, F
Citation: E. Couturier et al., HIV-1 diversity in France, 1996-1998, AIDS, 14(3), 2000, pp. 289-296
Safety of cryopreservation straws for human gametes or embryos: a preliminary study with human immunodeficiency virus-1
Authors: Benifla, JL Letur-Konirsch, H Collin, G Devaux, A Kuttenn, F Madelenat, P Brun-Vezinet, F Feldmann, G
Citation: Jl. Benifla et al., Safety of cryopreservation straws for human gametes or embryos: a preliminary study with human immunodeficiency virus-1, HUM REPR, 15(10), 2000, pp. 2186-2189
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
Authors: Descamps, D Flandre, P Calvez, V Peytavin, G Meiffredy, V Collin, G Delaugerre, C Robert-Delmas, S Bazin, B Aboulker, JP Pialoux, G Raffi, F Brun-Vezinet, F
Citation: D. Descamps et al., Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy, J AM MED A, 283(2), 2000, pp. 205-211
Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel
Authors: Hirsch, MS Brun-Vezinet, F D'Aquila, RT Hammer, SM Johnson, VA Kuritzkes, DR Loveday, C Mellors, JW Clotet, B Conway, B Demeter, LM Vella, S Jacobsen, DM Richman, DD
Citation: Ms. Hirsch et al., Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel, J AM MED A, 283(18), 2000, pp. 2417-2426
env Sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area
Authors: Corbet, S Muller-Trutwin, MC Versmisse, P Delarue, S Ayouba, A Lewis, J Brunak, S Martin, P Brun-Vezinet, F Simon, F Barre-Sinoussi, F Mauclere, P
Citation: S. Corbet et al., env Sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area, J VIROLOGY, 74(1), 2000, pp. 529-534
Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the Delta lamivudine roll-over study
Authors: Masquelier, B Descamps, D Carriere, I Ferchal, F Collin, G Denayrolles, M Ruffault, A Chanzy, B Izopet, J Buffet-Janvresse, C Schmitt, MP Race, E Fleury, HJA Aboulker, JP Yeni, P Brun-Vezinet, F
Citation: B. Masquelier et al., Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the Delta lamivudine roll-over study, ANTIVIR TH, 4(2), 1999, pp. 69-77
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patientswith persistent CMV viremia
Authors: Salmon-Ceron, D Fillet, AM Aboulker, JP Gerard, L Houhou, N Carriere, I Ostinelli, J Vilde, JL Brun-Vezinet, F Leport, C
Citation: D. Salmon-ceron et al., Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patientswith persistent CMV viremia, CLIN INF D, 28(4), 1999, pp. 901-905
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial
Authors: Been-Tiktak, AMM Boucher, CAB Brun-Vezinet, F Joly, V Mulder, JW Jost, J Cooper, DA Moroni, M Gatell, JM Staszewski, S Colebunders, R Stewart, GJ Hawkins, DA Johnson, MA Parkin, JM Kennedy, DH Hoy, JF Borleffs, JCC
Citation: Amm. Been-tiktak et al., Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial, INT J ANT A, 11(1), 1999, pp. 13-21
An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome
Authors: Aboulker, JP Babiker, AG Flandre, P Gazzard, B Loveday, C Nunn, AJ Goudsmit, J Huraux, JM van der Noorda, J Weiss, R Boucher, C Schurrman, R Brun-Vezinet, F Descamps, D Jeffries, D Tedder, R Weber, J Darbyshire, JH Reiss, P Weverling, G
Citation: Jp. Aboulker et al., An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome, AIDS, 13(5), 1999, pp. 565-573
HIV-1 subtypes and plasma RNA quantification
Authors: Damond, F Apetrei, C Descamps, D Brun-Vezinet, F Simon, F
Citation: F. Damond et al., HIV-1 subtypes and plasma RNA quantification, AIDS, 13(2), 1999, pp. 286-288
HIV-1 RNA response to antiretroviral treatment in 1280 participants in theDelta Trial: an extended virology study
Authors: Aboulker, JP Babiker, AG Brun-Vezinet, F Darbyshire, JH Flandre, P Gazzard, B Nunn, AJ Goodall, R Aber, V Bragman, K Breckenridge, AM Carbon, C Charreau, I Chene, G Collis, P Cooper, D Dormont, J Fiddian, P Flepp, M Goebel, FD Hooker, M Lange, J Luthy, R Peto, TEA Reiss, P Seligmann, M Stone, AB Thomis, J Vella, S Walckenaer, G Warrell, D Weller, IVD Wilber, R Yeni, P Yeo, J Withnall, R Goudsmit, J Huraux, JM van der Noorda, J Weiss, R Boucher, C Schuurman, R Descamps, D Jeffries, D Tedder, R Weber, J Krzyanowski, C Weverling, G
Citation: Jp. Aboulker et al., HIV-1 RNA response to antiretroviral treatment in 1280 participants in theDelta Trial: an extended virology study, AIDS, 13(1), 1999, pp. 57-65
Variability of human immunodeficiency viruses type 1.
Authors: Brun-Vezinet, F Damond, F Simon, F
Citation: F. Brun-vezinet et al., Variability of human immunodeficiency viruses type 1., B S PATH EX, 92(4), 1999, pp. 261-263
Assessment of codon 215 mutation in 10 patients with slow progression of HIV infection, on long-term zidovudine monotherapy
Authors: Leport, C Descamps, D Lacassin, F Collin, G Tilly, F Vilde, JL Brun-Vezinet, F
Citation: C. Leport et al., Assessment of codon 215 mutation in 10 patients with slow progression of HIV infection, on long-term zidovudine monotherapy, MED MAL INF, 28(10), 1998, pp. 652-657
Risultati: 1-25 |